PLK1 억제제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• Two classes of small-molecule PLK1 inhibitors have been developed: ATP-competitive inhibitors targeting the kinase domain, and non-ATP-competitive inhibitors targeting the polo-box domain (PBD).
• The emerging drug pipeline for PLK1 inhibitors is diverse and includes several promising candidates, such as Onvansertib (Cardiff Oncology), Plogosertib (Bio Green Med Solution), BAL0891 (SillaJen), Volasertib(Oncoheroes Biosciences), and others. Most candidates are in early-to-mid stages; preclinical, Phase I, and Phase II development.
• Despite its central role in driving tumor progression, invasion, and metastasis no PLK1 inhibitor has yet received marketing approval, underscoring the translational challenges in effectively targeting this kinase.

DelveInsight's "PLK1 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report delivers an in-depth understanding of PLK1 Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The PLK1 Inhibitor market report provides insights around existing treatment practices in patients with PLK1 Inhibitor, approved (if any) and emerging PLK1 Inhibitor, market share of individual therapies, patient pool eligible for treatment with PLK1 Inhibitor, along with current and forecasted 7MM PLK1 Inhibitor market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new PLK1 Inhibitor in different geographies, along with insights on PLK1 Inhibitor pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

PLK1 Inhibitor Overview

Polo-like kinases (PLKs) are a family of five serine/threonine kinases (PLK1-PLK5), with PLK1 being the most extensively studied. PLK1 plays a central role in cell cycle regulation, particularly in mitotic entry, centrosome function, spindle assembly, chromosome segregation, and cytokinesis. Emerging evidence also highlights additional non-cell cycle roles through newly identified substrates.

PLK1 dysregulation is observed across multiple tumor types and contributes to tumor progression. It is frequently overexpressed at both mRNA and protein levels versus normal tissue, with higher expression linked to poor prognosis. PLK1 overexpression is also associated with therapy resistance, while its inhibition may restore sensitivity to chemo- and radiotherapy.

Target Patient Pool Analysis

• In the United States, the total cases of NSCLC by age distribution were ~64,000 and ~139,000 cases for the age group <65 years and >=65 years, respectively, in 2025. As per the analysis, these cases are expected to rise for their respective age group by 2036.
• In 2025, the stage-specific incidence of Gastric Cancer showed a clear skew toward advanced disease, with ~12,000 cases diagnosed at Stage IV, followed by ~8,500 at Stage III, compared to ~5,500 and ~4,800 cases at Stages I and II, respectively, indicating a substantial proportion of patients presenting at later stages and highlighting ongoing gaps in early detection.
• According to Surveillance, Epidemiology, and End Results (SEER) Program estimates for 2025, Ovarian Cancer accounted for approximately 20,890 new cases in the United States, corresponding to an incidence rate of 10.3 per 100,000 women per year, reflecting a relatively moderate but clinically significant disease burden.
• Colorectal Cancer is the third most common cancer globally, accounting for around 10% of all cases, primarily affecting individuals aged 50 and above; however, a rising incidence among adults aged 30-50 in certain settings highlights an emerging early-onset burden.

PLK1 Inhibitor Drug Chapters

The drug chapter segment of the PLK1 Inhibitor report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the PLK1 Inhibitor clinical trial details, pharmacological action, agreements and collaborations related to PLK1 Inhibitor, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

PLK1 Inhibitor Emerging Drugs

Onvansertib: Cardiff Oncology

Onvansertib is Cardiff Oncology's investigational oral, highly selective PLK1 inhibitor being developed mainly in combination with standard therapies for RAS/KRAS-mutant metastatic colorectal cancer and other solid tumors. It is currently being evaluated in many trials:

Metastatic Colorectal Cancer (RAS-mutant): 1st line Phase II (randomized, ongoing); 2nd line Phase Ib/II (completed)

Chronic Myelomonocytic Leukemia: 2nd line Phase I (expansion ongoing)

Metastatic Pancreatic Ductal Adenocarcinoma: 1st line Phase II (ongoing); 2nd line Phase II (completed)

Small Cell Lung Cancer: 2nd line Phase II (ongoing)

Triple-Negative Breast Cancer: 2nd line Phase II (ongoing)

Plogosertib: Bio Green Med Solution

Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of Plogosertib in leukemias and solid tumors. Plogosertib was designed with improved pharmaceutical properties over earlier clinical-stage PLK inhibitors. Recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer.

Solid Tumors & Lymphoma: Phase I/II trial of oral plogosertib to establish Phase II dosing and assess early clinical activity across multiple cancer types

Leukemias: Phase I/II trial planned to evaluate dosing and activity in hematologic malignancies.

BAL0891: SillaJen

BAL0891 is SillaJen's investigational, first-in-class dual mitotic checkpoint inhibitor that targets TTK and PLK1 to disrupt cancer cell division and drive tumor cell death. It is being developed for solid tumors and is also being explored as a combination partner with immunotherapy. It is currently being evaluated in Phase I for solid tumors.

SillaJen announced that it had entered into a clinical drug support agreement with BeiGene on January 6, 2025, under which BeiGene agreed to supply its PD-1 inhibitor tislelizumab for a combination clinical trial with SillaJen's investigational asset BAL0891 in solid tumors. BAL0891.

Recent Developments in the PLK1 Inhibitor Market

• In March 2026, Cardiff Oncology announced that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan will be presented at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
• In October 2025, the Bio Green Med Solution entered into an asset purchase agreement with Tethra Biosciences to divest certain assets, including patent rights for plogosertib, for USD 300,000 upfront with up to USD 170,000 in milestone payments.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on PLK1 Inhibitor as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of PLK1 Inhibitor, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

PLK1 Inhibitor Market Outlook

This section will include details on changing PLK1 Inhibitor market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

PLK1 Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential PLK1 Inhibitor already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

PLK1 Inhibitor Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

PLK1 Inhibitor Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for PLK1 Inhibitor.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on PLK1 Inhibitor' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on PLK1 Inhibitor addressable patient pool
• A detailed review of the PLK1 Inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM PLK1 Inhibitor market.
• Market Size of Inhibitors by therapies and indication will be provided

PLK1 Inhibitor Report Key Strengths

• 11 Years PLK1 Inhibitor Market Forecast
• The 7MM Coverage
• PLK1 Inhibitor Competitive Landscape of current and emerging therapies
• PLK1 Inhibitor Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• PLK1 Inhibitor Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the PLK1 Inhibitor total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for PLK1 Inhibitor market growth?
• Which drug is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of PLK1 Inhibitor?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the PLK1 Inhibitor Market.
• Understand the existing PLK1 Inhibitor market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of PLK1 Inhibitor

4. Key Events

5. PLK1 Inhibitor Market Overview At A Glance

• 5.1. Market Share (%) Distribution of PLK1 Inhibitor By Therapy in 2025
• 5.2. Market Share (%) Distribution of PLK1 Inhibitor By Therapy in 2036

6. Background And Overview

7. Target Population

8. PLK1 Inhibitor Marketed Drugs

• 8.1. Key Competitors
  • 8.1.1. Product Description
  • 8.1.2. Regulatory Milestones
  • 8.1.3. Other Developmental Activities
  • 8.1.4. Ongoing Clinical Development
  • 8.1.5. Safety and Efficacy

9. PLK1 Inhibitor Emerging Drugs

• 9.1. Key Competitors
  • 9.1.1. Product Description
  • 9.1.2. Other Development Activities
  • 9.1.3. Clinical Development
    • 9.1.3.1. Clinical Trials Information
  • 9.1.4. Safety and Efficacy

10. PLK1 Inhibitor: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of PLK1 Inhibitor in the 7MM
  • 10.4.1. Market Size of PLK1 Inhibitor By Therapies In the 7MM
  • 10.4.2. Market Size of PLK1 Inhibitor By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of PLK1 Inhibitor in the United States
  • 10.6.2. Market Size of PLK1 Inhibitor By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of PLK1 Inhibitor in EU4 and the UK
  • 10.7.2. Market Size of PLK1 Inhibitor By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of PLK1 Inhibitor in Japan
  • 10.8.2. Market Size of PLK1 Inhibitor By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight